^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Zercepac (trastuzumab biosimilar) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
07/27/2020
Excerpt:
Zercepac is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):...in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.
Secondary therapy:
Aromatase inhibitor
